Aurora Spine (ASG) Q1 2025 earnings summary

Executive summary

• Achieved record Q1 2025 revenue of $4.42 million, up 10% year-over-year, driven by proprietary product platforms, increased adoption, and expanded sales team.

• Focused on building momentum through new product launches, deeper engagement with doctors, and expanded R&D investments.

• FDA granted 510(k) clearance for the AERO Facet Fusion System, expanding the product portfolio.

• Closed data collection in the REFINE study for the ZIP Interspinous Fixation device, with results to be presented at a major industry conference.

• Continued investment in clinical studies to support product adoption and market leadership.

Financial highlights

• Q1 2025 revenue was $4.42 million, up 10% year-over-year from $4.01 million, attributed to higher procedure volumes and targeted marketing.

• Gross margin was 58%, down from 61.9% in Q1 2024, impacted by higher shipping and distributor costs.

• Operating expenses rose to $2.9 million from $2.75 million, mainly due to higher compensation and training.

• EBITDA/EBITDAC was negative $0.02 million, compared to positive $0.12 million a year ago, reflecting higher expenses from sales team expansion.

• Net loss was $0.35 million, compared to a $0.267 million loss in Q1 2024; EPS remained at $(0.00) per share.

• Ended the quarter with $488,693 in cash, down from $825,621 at year-end; accounts receivable elevated but mostly collected post-quarter.

Outlook and guidance

• Management expects continued year-over-year revenue growth, targeting at least 20% annual growth and profitability for 2025.

• Anticipates strong contributions from new product launches (DEXA-L, Aero) in the second half of 2025.

• Focus remains on minimally invasive technologies and expanding the proprietary product portfolio.

• Confident in capital structure and no need to raise additional funds.